SCHEMBL3536581

SCHEMBL3536581

CCN1CCN(c2ccc3nc(-c4n[nH]c5ccc(Oc6cccc(OC)c6)cc45)n(C)c3c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.52
LRRK2 Q5S007 7/20 0.49
FGFR1 P11362 4/20 0.45
FLT1 P17948 1/20 0.42
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
KDR P35968 1/20 0.41
DRD2 P14416 3/20 0.41
DRD4 P21917 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HRH1 P35367 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3612553 0.94 ABL1 (0.51) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3535310 0.93 FGFR1 (0.49) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3537434 0.91 FGFR1 (0.44) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3544838 0.89 ABL1 (0.53) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3540571 0.88 FGFR1 (0.46) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3540626 0.88 FGFR1 (0.44) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3535696 0.87 FGFR1 (0.44) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3544861 0.85 FGFR1 (0.44) ABL1LRRK2FGFR1FLT1FGFR2
SCHEMBL3539022 0.84 FGFR1 (0.43) ABL1LRRK2FGFR1FLT1KDR
SCHEMBL3532764 0.84 FGFR1 (0.52) ABL1LRRK2FGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK ABL1 1/4885LRRK2 672/4885FGFR1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.